Association Between Treatments and Short-Term Biochemical Improvements and Clinical Outcomes in Post-Severe Acute Respiratory Syndrome Coronavirus-2 Inflammatory Syndrome
Copyright © 2021 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies..
OBJECTIVES: To 1) analyze the short-term biochemical improvements and clinical outcomes following treatment of children with post-severe acute respiratory syndrome coronavirus-2 inflammatory syndrome (multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2) admitted to U.K. PICUs and 2) collate current treatment guidance from U.K. PICUs.
DESIGN: Multicenter observational study.
SETTING: Twenty-one U.K. PICUs.
PATIENTS: Children (< 18 yr) admitted to U.K. PICUs between April 1, 2020, and May 10, 2020, fulfilling the U.K. case definition of pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Routinely collected, deidentified data were analyzed. Propensity score and linear mixed effects models were used to analyze the effect of steroids, IV immunoglobulin, and biologic agents on changes in C-reactive protein, platelet counts, and lymphocyte counts over the course of PICU stay. Treatment recommendations from U.K. clinical guidelines were analyzed. Over the 6-week study period, 59 of 78 children (76%) received IV immunoglobulin, 57 of 78 (73%) steroids, and 18 of 78 (24%) a biologic agent. We found no evidence of a difference in response in clinical markers of inflammation between patients with multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 who were treated with IV immunoglobulin, steroids, or biologics, compared with those who were not. By the end of the study period, most patients had received immunomodulation. The 12 patients who did not receive any immunomodulators had similar decrease in inflammatory markers as those treated. Of the 14 guidelines analyzed, the use of IV immunoglobulin, steroids, and biologics was universally recommended.
CONCLUSIONS: We were unable to identify any short-term benefit from any of the treatments, or treatment combinations, administered. Despite a lack of evidence, treatment guidelines for multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 have become very similar in advising step-wise treatments. Retaining clinical equipoise regarding treatment will allow clinicians to enroll children in robust clinical trials to determine the optimal treatment for this novel important condition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies - 22(2021), 5 vom: 01. Mai, Seite e285-e293 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davies, Patrick [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulins, Intravenous |
|---|
| Anmerkungen: |
Date Completed 10.05.2021 Date Revised 11.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/PCC.0000000000002728 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323230156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323230156 | ||
| 003 | DE-627 | ||
| 005 | 20231225183733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PCC.0000000000002728 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323230156 | ||
| 035 | |a (NLM)33767074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Davies, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between Treatments and Short-Term Biochemical Improvements and Clinical Outcomes in Post-Severe Acute Respiratory Syndrome Coronavirus-2 Inflammatory Syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2021 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. | ||
| 520 | |a OBJECTIVES: To 1) analyze the short-term biochemical improvements and clinical outcomes following treatment of children with post-severe acute respiratory syndrome coronavirus-2 inflammatory syndrome (multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2) admitted to U.K. PICUs and 2) collate current treatment guidance from U.K. PICUs | ||
| 520 | |a DESIGN: Multicenter observational study | ||
| 520 | |a SETTING: Twenty-one U.K. PICUs | ||
| 520 | |a PATIENTS: Children (< 18 yr) admitted to U.K. PICUs between April 1, 2020, and May 10, 2020, fulfilling the U.K. case definition of pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 | ||
| 520 | |a INTERVENTIONS: None | ||
| 520 | |a MEASUREMENTS AND MAIN RESULTS: Routinely collected, deidentified data were analyzed. Propensity score and linear mixed effects models were used to analyze the effect of steroids, IV immunoglobulin, and biologic agents on changes in C-reactive protein, platelet counts, and lymphocyte counts over the course of PICU stay. Treatment recommendations from U.K. clinical guidelines were analyzed. Over the 6-week study period, 59 of 78 children (76%) received IV immunoglobulin, 57 of 78 (73%) steroids, and 18 of 78 (24%) a biologic agent. We found no evidence of a difference in response in clinical markers of inflammation between patients with multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 who were treated with IV immunoglobulin, steroids, or biologics, compared with those who were not. By the end of the study period, most patients had received immunomodulation. The 12 patients who did not receive any immunomodulators had similar decrease in inflammatory markers as those treated. Of the 14 guidelines analyzed, the use of IV immunoglobulin, steroids, and biologics was universally recommended | ||
| 520 | |a CONCLUSIONS: We were unable to identify any short-term benefit from any of the treatments, or treatment combinations, administered. Despite a lack of evidence, treatment guidelines for multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 have become very similar in advising step-wise treatments. Retaining clinical equipoise regarding treatment will allow clinicians to enroll children in robust clinical trials to determine the optimal treatment for this novel important condition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Lillie, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Prayle, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a du Pré, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Mae |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan Kanthimathinathan, Hari |e verfasserin |4 aut | |
| 700 | 1 | |a Playfor, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Deep, Akash |e verfasserin |4 aut | |
| 700 | 1 | |a Brierley, Joe |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Gareth |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammad, Zoha |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Davinder |e verfasserin |4 aut | |
| 700 | 1 | |a Jardine, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Shetty, Nayan |e verfasserin |4 aut | |
| 700 | 1 | |a Worrall, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Ruchi |e verfasserin |4 aut | |
| 700 | 1 | |a Koul, Ashwani |e verfasserin |4 aut | |
| 700 | 1 | |a Whittaker, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Harish |e verfasserin |4 aut | |
| 700 | 1 | |a Ramnarayan, Padmanabhan |e verfasserin |4 aut | |
| 700 | 1 | |a Scholefield, Barnaby R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies |d 2000 |g 22(2021), 5 vom: 01. Mai, Seite e285-e293 |w (DE-627)NLM124299717 |x 1529-7535 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:5 |g day:01 |g month:05 |g pages:e285-e293 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PCC.0000000000002728 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 5 |b 01 |c 05 |h e285-e293 | ||